Home
Search Center
Journal List
CMA
Contact US
|
Chinese
You Position:
Home
> Paper
Family companion between patients with coronavirus disease 2019: a retrospective observational study
( views:0, downloads:0 )
Author:
No author available
Journal Title:
Chinese Medical Journal
Issue:
20
DOI:
10.1097/CM9.0000000000001114
Key Word:
No keyword available
Abstract: No abstract available
Reference
[1]Liu Shan-ying,Liang Ying,LIN Tian-xin,etc.
MEK1 and MEK2 differentially regulate human insulin-and insulin glargine-induced human bladder cancer T24 cell proliferation
[J].2012,(23).
[2]Brea, Elliott J.,Oh, Claire Y.,Manchado, Eusebio,etc.
Kinase Regulation of Human MHC Class I Molecule Expression on Cancer Cells
[J].2016,4(11).
[3]Carminia Maria,Della Corte,Giusi,Barra,Vincenza,Ciaramella,etc.
Antitumor activity of dual blockade of PD-L1 and MEK in NSCLC patients derived three-dimensional spheroid cultures.
[J].2019,38(1).
[4]Ebert, Peter J. R.,Cheung, Jeanne,Yang, Yagai,etc.
MAP Kinase Inhibition Promotes T Cell and Anti-tumor Activity in Combination with PD-L1 Checkpoint Blockade
[J].2016,44(3).
[5]Samatar Ahmed A.,Poulikakos Poulikos I..
Targeting RAS–ERK signalling in cancer: promises and challenges
[J].2014,13(12).
[6]Ribas, Antoni,Lawrence, Donald,Atkinson, Victoria,etc.
Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma
[J].2019,25(6).
[7]Lee, Jong Woo,Zhang, Yu,Eoh, Kyung Jin,etc.
The Combination of MEK Inhibitor With Immunomodulatory Antibodies Targeting Programmed Death 1 and Programmed Death Ligand 1 Results in Prolonged Survival in Kras/p53-Driven Lung Cancer
[J].2019,14(6).
[8]Boni A,Cogdill AP,Flaherty KT,etc.
Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function.
[J].2010,70(13).
[9]Ambrogio, Chiara,Kohler, Jens,Zhou, Zhi-Wei,etc.
KRAS Dimerization Impacts MEK Inhibitor Sensitivity and Oncogenic Activity of Mutant KRAS
[J].2018,172(4).
[10]Kuske, Marvin,Westphal, Dana,Wehner, Rebekka,etc.
Immunomodulatory effects of BRAF and MEK inhibitors: Implications for Melanoma therapy
[J].2018,136.
[11]Erkes, Dan A.,Cai, Weijia,Sanchez, Ileine M.,etc.
Mutant BRAF and MEK Inhibitors Regulate the Tumor Immune Microenvironment via Pyroptosis
[J].2020,10(2).
[12]Helen,Adderley,Fiona H,Blackhall,Colin R,Lindsay.
KRAS-mutant non-small cell lung cancer: Converging small molecules and immune checkpoint inhibition.
[J].2019,41.
[13]Seong-Ho Kang,Bhumsuk Keam,Yong-Oon Ahn,etc.
Inhibition of MEK with trametinib enhances the efficacy of anti-PD-L1 inhibitor by regulating anti-tumor immunity in head and neck squamous cell carcinoma
[J].2019,8(1).
[14]Haratani, K.,Hayashi, H.,Tanaka, T.,etc.
Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatment
[J].2017,28(7).
[15]Liu, Li,Mayes, Patrick A.,Eastman, Stephen,etc.
The BRAF and MEK Inhibitors Dabrafenib and Trametinib: Effects on Immune Function and in Combination with Immunomodulatory Antibodies Targeting PD-1, PD-L1, and CTLA-4
[J].2015,21(7).
[16]Edmund, Poon,Stefanie, Mullins,Amanda, Watkins,etc.
The MEK inhibitor selumetinib complements CTLA-4 blockade by reprogramming the tumor immune microenvironment.
[J].2017,5(1).
[17]Satomi Watanabe,Hidetoshi Hayashi,Koji Haratani,etc.
Mutational activation of the epidermal growth factor receptor down‐regulates major histocompatibility complex class I expression via the extracellular signal‐regulated kinase in non–small cell lung cancer
[J].2019,110(1).
WanfangData CO.,Ltd All Rights Reserved
About WanfangData
|
Contact US
Healthcare Department, Fuxing Road NO.15, Haidian District Beijing, 100038 P.R.China
Tel:+86-010-58882616 Fax:+86-010-58882615 Email:
yiyao@wanfangdata.com.cn